ArticleCell communication and signaling : CCS2025
SRY mediates male-specific susceptibility to acute liver injury.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsSex-determining region on the Y chromosome (SRY), a male-specific gene, can promote the development of various liver diseases including liver fibrosis, hepatocellular carcinoma. Its role in acute liver injury (ALI), however, remains elusive. Here, we aimed to investigate the effects of SRY on ALI.
methodsWe constructed hepatocyte-specific Sry-overexpressing transgenic (Sry-TG) and hepatocyte-specific Sry knockout (Sry
resultsSRY expression was markedly upregulated in the livers of both male patients and mice with ALI. Sry-TG mice exhibited significantly exacerbated liver injury and increased apoptosis and oxidative stress. In contrast, the male Sry
conclusionsOur results suggest that greater SRY expression in males may account for the susceptibility of males ALI. Dutasteride binds specifically to SRY and inhibits its expression, making it a promising therapy for the clinical treatment of ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.